Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 25/5/2020
SIETES contiene 93010 citas

 
 
 1 a 20 de 1874 siguiente >>
Presentar resultados
Seleccionar todas
2. Cita con resumen
Nici L, Mammen MJ, Charbek E, Alexander PE, Au DH, Boyd C, Criner GJ, Donaldson GC, Dreher M, Fan VS, Gershon AS, et al.. Pharmacologic management of chronic obstructive pulmonary disease. An official American Thoracic Society clinical practice guideline . Am J Respir Crit Care Med 2020;201:1 de mayo. [Ref.ID 103620]
3. Cita con resumen
Barnett ML. Opioid prescribing in the midst of crisis — Myths and realities. N Engl J Med 2020;382:19 de marzo. [Ref.ID 103579]
5. Cita con resumen
Just KS, Dormann H, Böhme M, Schurig M, Schneider KL, Steffens M, Dunow S, Plank-Kiegele B, Ettrich K, Seufferlein T, Gräff I, Igel S, Schricker S, Jaeger SU, Schwab MStingl J. Personalising drug safety—results from the multi-centre prospective observational study on Adverse Drug Reactions in Emergency Departments (ADRED). Eur J Clin Pharmacol 2020;76:marzo. [Ref.ID 103531]
6. Cita con resumen
Mahase E. Gabapentinoids: has reclassification really solved the problem?. BMJ 2020;368:13 de enero. [Ref.ID 103509]
7. Cita con resumen
9. Cita con resumen
Smith BH, Fletcher EH, Calvin LA. Opioid prescribing is rising in many countries. BMJ 2019;367:17 de octubre. [Ref.ID 103203]
10.Enlace a cita original Cita con resumen
Taylor P. J&J hit by $8bn judgment for man claiming breast growth due to Risperdal. PMLiVE 2019:9 de octubre. [Ref.ID 103192]
12. Cita con resumen
Beddoes ZM. Johnson & Johnson, Purdue and other opioid-peddlers face a reckoning. The Economist 2019:1. [Ref.ID 103165]
13.Enlace a cita original Cita con resumen
Finnerub NB. Nonnarcotic methods of pain management. N Engl J Med 2019;380:20 de junio. [Ref.ID 103139]
14.Enlace a cita original Cita con resumen
Schiek S, Hildebrandt K, Zube O, Bertsche T. Fall-risk-increasing adverse reactions - is there value in easily accessible drug information? A case-control study. Eur J Clin Pharmacol 2019;75:junio. [Ref.ID 103137]
15.Enlace a cita original Cita con resumen
Thiels CA, Habermann EB, Heffery MM. Chronic use of tramadol after acute pain episode: cohort study. BMJ 2019;365:14 de mayo. [Ref.ID 103126]
16.Enlace a cita original Cita con resumen
Hurd YL, Spriggs S, Alishayev J, Winkel G, Gurgov K, Kudrich C, Oprescu AM, Salsitz E. Cannabidiol for the reduction of cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder: A double-blind randomized placebo-controlled trial. Am J Psychiatry 2019:21 de mayo. [Ref.ID 103125]
17.Enlace a cita originalTiene citas relacionadas Cita con resumen
Jeong S, Tchoe HJ, Shin JY. All-cause mortality associated with tramadol use: a case-crossover study. Drug Saf 2019;42:junio. [Ref.ID 103119]
18.Enlace a cita original Cita con resumen
Haight BR, Learned SM, Lafont CM, Fudala PJ, Zhao Y, Garofalo AS, Greenwald MK, Nadipelli VR, Linq W, Heidbreder C, RB-US-13-0001 Study Investigators. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2019;393:23 de febrero. [Ref.ID 103111]
19.Enlace a cita original Cita con resumen
Hedenmalm K, Slattery J, Skibicka-Stepien I, Kurz X, Morales D. Prescribing patterns of tramadol in adults in IMS® primary care databases in France and Germany between 1 January 2006 and 30 June 2016. Eur J Clin Pharmacol 2019;75:5. [Ref.ID 103092]
20.Enlace a cita original Cita con resumen
Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) — Pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med 2019:10 de abril. [Ref.ID 103090]
Seleccionar todas
 
 1 a 20 de 1874 siguiente >>